Published in Antimicrob Agents Chemother on March 01, 2003
In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates. Antimicrob Agents Chemother (2006) 0.84
Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources. Antimicrob Agents Chemother (2007) 0.83
Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum. Antimicrob Agents Chemother (2005) 0.76
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother (2000) 3.08
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother (1994) 2.21
Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis (1996) 1.87
Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis (2000) 1.83
Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother (2001) 1.79
In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother (1996) 1.76
Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother (1998) 1.73
Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother (2001) 1.44
Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother (1999) 1.38
The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother (2002) 1.27
The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections. Am J Surg (1995) 1.22
Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrob Agents Chemother (1999) 1.12
Prevalence of beta-lactamase-producing strains among 149 anaerobic gram-negative rods isolated from periodontal pockets. Oral Microbiol Immunol (1999) 1.09
Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob Agents Chemother (1999) 1.06
Quinolone activity against anaerobes. Drugs (1999) 1.04
Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa. Eur J Clin Microbiol Infect Dis (1999) 1.02
Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates. Antimicrob Agents Chemother (2002) 0.97
Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. Int J Antimicrob Agents (2001) 0.94
Antimicrobial resistance in human oral and intestinal anaerobic microfloras. Antimicrob Agents Chemother (1993) 0.89
Prevalence of the carbapenemase gene (cfiA) among clinical and normal flora isolates of Bacteroides species in Hungary. J Med Microbiol (2000) 0.88
Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin Infect Dis (1993) 0.87
Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci. J Antimicrob Chemother (2001) 0.84
Anti-anaerobic activity of antibacterial agents. Expert Opin Investig Drugs (2001) 0.82
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. Diagn Microbiol Infect Dis (2001) 0.82
Anaerobic infection therapy. Int J Antimicrob Agents (2000) 0.81
Prevalence and degree of expression of the carbapenemase gene (cfiA) among clinical isolates of Bacteroides fragilis in Nottingham, UK. J Antimicrob Chemother (1999) 0.79
Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals. Clin Infect Dis (1993) 0.87
Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media. Clin Infect Dis (1996) 0.80
Susceptibility results for the Bacteroides fragilis group: comparison of the broth microdilution and agar dilution methods. Clin Infect Dis (1995) 0.75